المؤلفون: Finan T. Hindam, Basma M. Eltanany, Amal M. Abou Al Alamein, Rasha M. El Nashar, Reham M. Arafa

المصدر: BMC Chemistry, Vol 18, Iss 1, Pp 1-16 (2024)

مصطلحات موضوعية: Antiparkinson drugs, Carbidopa, Entacapone, Differential Pulse Voltammetry, Levodopa, PLS, Chemistry, QD1-999

الوصف: Abstract An electroanalytical methodology was developed by direct differential pulse voltammetric (DPV) measurement of Levodopa (LD), Carbidopa (CD) and Entacapone (ENT) mixture using bare glassy carbon electrode (GCE) in Britton Robinson (BR) buffer (pH = 2.0). A multivariate calibration model was then applied to the exported preprocessed voltammetric data using partial least square (PLS) as a chemometric tool. Additionally, the model was cross-validated and the number of latent variables (LVs) were determined to produce a reliable model for simultaneous quantitation of the three drugs either in their synthetic mixtures or in their marketed pharmaceutical formulation with high accuracy and precision. Data preprocessing was used to tackle the problem of lacking bi-linearity which is commonly found in electrochemical data. The proposed chemometric model was able to provide fast and reliable technique for quantitative determination of antiparkinson drugs in their dosage forms. This was successfully achieved by utilizing sixteen mixtures as calibration set and nine mixtures as validation set. The percent recoveries for LD, CD and ENT were found to be 100.05% ± 1.28%, 100.04% ± 0.53% and 99.99% ± 1.25%, respectively. The obtained results of the proposed method were statistically compared to those of a previously reported High Performance Liquid Chromatography (HPLC) methodology. Finally, the presented analytical method strongly supports green analytical chemistry regarding the minimization of potentially dangerous chemicals and solvents, as well as reducing energy utilization and waste generation.

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/2661-801XTest

الوصول الحر: https://doaj.org/article/0537b2df158f401b8ed82e85f5d0ac2eTest

المؤلفون: Marjaana Koponen, J. Simon Bell, Samanta Lalic, Rosie Watson, Anne M. Koivisto, Jenni Ilomäki

المصدر: BMC Geriatrics, Vol 22, Iss 1, Pp 1-9 (2022)

مصطلحات موضوعية: Antiparkinson drugs, Parkinson’s disease, Pharmacoepidemiology, Australia, Sex differences, Geriatrics, RC952-954.6

الوصف: Abstract Background Guidelines highlight the importance of an individualized approach to treatment initiation for Parkinson’s disease. Our aim was to investigate initiation of anti-Parkinson medication in Australia from 2013–2018, and to determine factors predicting choice of initial treatment. Methods Cohort of new-users (N = 4,887) of anti-Parkinson medication aged ≥ 40 years were identified from a 10% random representative sample of national medication dispensing data from July-2013 to June-2018. Changes in treatment initiation were examined across the whole cohort and stratified by age and sex. Results Treatment initiation was most frequent with levodopa followed by non-ergot dopamine agonists (DAs) and anticholinergics. Two thirds initiated with levodopa across the study period. Initiation with non-ergot DAs increased from 22 to 27% (rate ratio, RR 1.23, 95% confidence interval, CI 1.02–1.47) and initiation with anticholinergics decreased from 6.9% to 2.4% (RR 0.34, 95% CI 0.21–0.55) from 2013–2018. Among persons aged ≥ 65 years, one third of women and one fourth of men initiated on levodopa. Among women aged

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/1471-2318Test

الوصول الحر: https://doaj.org/article/31600907ba1544c29516d2629ff7faabTest

المؤلفون: Koponen, Marjaana, Bell, J. Simon, Lalic, Samanta, Watson, Rosie, Koivisto, Anne M., Ilomäki, Jenni

المساهمون: Department of Neurosciences, University of Helsinki, HUS Internal Medicine and Rehabilitation, Geriatrian yksikkö

مصطلحات موضوعية: Antiparkinson drugs, Parkinson's disease, Pharmacoepidemiology, Australia, Sex differences, GUIDELINES, MANAGEMENT, General medicine, internal medicine and other clinical medicine, Neurosciences

الوصف: Background Guidelines highlight the importance of an individualized approach to treatment initiation for Parkinson's disease. Our aim was to investigate initiation of anti-Parkinson medication in Australia from 2013-2018, and to determine factors predicting choice of initial treatment. Methods Cohort of new-users (N = 4,887) of anti-Parkinson medication aged >= 40 years were identified from a 10% random representative sample of national medication dispensing data from July-2013 to June-2018. Changes in treatment initiation were examined across the whole cohort and stratified by age and sex. Results Treatment initiation was most frequent with levodopa followed by non-ergot dopamine agonists (DAs) and anticholinergics. Two thirds initiated with levodopa across the study period. Initiation with non-ergot DAs increased from 22 to 27% (rate ratio, RR 1.23, 95% confidence interval, CI 1.02-1.47) and initiation with anticholinergics decreased from 6.9% to 2.4% (RR 0.34, 95% CI 0.21-0.55) from 2013-2018. Among persons aged >= 65 years, one third of women and one fourth of men initiated on levodopa. Among women aged < 65 years, rates of treatment initiation with DAs (37%) and levodopa (37%) were similar in 2013/2014 but initiation with DA exceeded levodopa thereafter. Among men aged < 65 years, treatment initiation with levodopa (44%-49%) remained more frequent than initiation with DAs (29%-32%) throughout the study period. Conclusions Treatment initiation with levodopa was most frequent among persons aged >= 65 years, consistent with current guidelines. Whilst the value of levodopa sparing strategies is unclear, treatment initiation with DA has become increasingly common relative to levodopa among women but not among men aged < 65 years. ; Peer reviewed

وصف الملف: application/pdf

العلاقة: Koponen , M , Bell , J S , Lalic , S , Watson , R , Koivisto , A M & Ilomäki , J 2022 , ' Treatment initiation for parkinson's disease in Australia 2013-2018 : a nation-wide study ' , BMC Geriatrics , vol. 22 , no. 1 , 483 . https://doi.org/10.1186/s12877-022-03095-3Test; http://hdl.handle.net/10138/345943Test; 3f0a0990-4d4a-436f-af3e-a763e0595284; 000805826900001

الإتاحة: http://hdl.handle.net/10138/345943Test

المؤلفون: Sarah Mendorf, Otto W. Witte, Hannah Zipprich, Tino Prell

المصدر: Frontiers in Neurology, Vol 11 (2020)

مصطلحات موضوعية: adherence, antiparkinson drugs, non-motor symptom, anxiety, depression, Neurology. Diseases of the nervous system, RC346-429

الوصف: Background: Nonadherence to medication is a common and serious issue in the treatment of patients with Parkinson's disease (PD). Among others, distinct nonmotor symptoms (NMS) were found to be associated with nonadherence in PD. Here, we aimed to confirm the association between NMS and adherence.Methods: In this observational study, the following data were collected: sociodemographic data, the German versions of the Movement Disorder Society-sponsored revision of the unified Parkinson's disease rating scale for motor function (MDS-UPDRS III), Hoehn and Yahr (H&Y) stage, levodopa equivalent daily dose (LEDD), Becks depression inventory II (BDI-II), nonmotor symptoms questionnaire (NMSQ), and the Stendal adherence to medication score (SAMS).Results: The final sample included 137 people with PD [54 (39.4%) females] with a mean age of 71.3 ± 8.2 years. According to SAMS, 10.9% of the patients were fully adherent, 73% were moderately nonadherent, and 16.1% showed clinically significant nonadherence. Nonadherence was associated with LEDD, BDI-II, education level, MDS-UPDRS III, and the NMSQ. The number of NMS was higher in nonadherent patients than in adherent patients. In the multiple stepwise regression analysis, the items 5 (constipation), 17 (anxiety), and 21 (falls) predicted nonadherence to medication. These NMSQ items also remained significant predictors for SAMS after correction for LEDD, MDS-UPDRS III, BDI-II, age, education level, gender, and disease duration.Conclusion: Our study, in principle, confirms the association between NMS burden and nonadherence in PD. However, in contrast to other clinical factors, the relevance of NMSQ in terms of nonadherence is low. More studies with larger sample sizes are necessary to explore the impact of distinct NMS on adherence.

وصف الملف: electronic resource

العلاقة: https://www.frontiersin.org/article/10.3389/fneur.2020.551696/fullTest; https://doaj.org/toc/1664-2295Test

الوصول الحر: https://doaj.org/article/834d8c631e3a4e38a62d1b71fb772aceTest

المؤلفون: Igor Straka, Michal Minár, Matej Škorvánek, Milan Grofik, Katarína Danterová, Ján Benetin, Egon Kurča, Andrea Gažová, Veronika Boleková, Kathryn A. Wyman-Chick, Ján Kyselovič, Peter Valkovič

المصدر: Frontiers in Neurology, Vol 10 (2019)

مصطلحات موضوعية: adherence, antiparkinson drugs, non-motor symptoms, Parkinson's disease, quality of life, Neurology. Diseases of the nervous system, RC346-429

الوصف: Background: Once-daily treatment formulation is associated with better adherence in comparison to more complex medication regimens. The study aimed to detect the extent of adherence to pharmacotherapy in Parkinson disease (PD) patients who take a minimum of three daily doses of drugs, and to identify factors associated with lower levels of adherence.Methods: The cohort was selected from non-demented PD patients. The 8-Item Morisky Medication Adherence Scale (MMAS-8), 8-Item Parkinson's Disease Questionnaire (PDQ-8), Geriatric Depression Scale (GDS), Non-Motor Symptom Assessment Scale (NMSS), 9-Item Wearing-off Questionnaire (WOQ-9), MDS-UPDRS III (motor examination), and IV (motor complications) scales were used in this study.Results: From a total of 124 subjects, 33.9% reported a high level of adherence, 29.8% reported a medium level of adherence, and 36.3% reported a low level of adherence to their pharmacotherapy. The level of non-adherence correlated with gender, longer disease duration, higher scores of PDQ-8, NMSS, WOQ-9, and MDS-UPDRS IV. Detailed analysis of NMSS demonstrated a correlation between the level of adherence and domains sleep/fatigue, mood/cognition, perceptual problems/hallucinations, attention/memory, and urinary symptoms. Independent risk factors for non-adherence were excessive daytime sleepiness, anhedonia, and forgetfulness.Conclusion: Non-adherence to more complicated medication regimens is frequent in PD patients and is associated with gender, longer PD duration, poorer quality of life, frequency and severity of non-motor symptoms, and more severe motor and non-motor fluctuations. Non-adherence was predicted by non-motor symptoms including fatigue, mood disturbances, and subjective cognitive complaints.

وصف الملف: electronic resource

العلاقة: https://www.frontiersin.org/article/10.3389/fneur.2019.00799/fullTest; https://doaj.org/toc/1664-2295Test

الوصول الحر: https://doaj.org/article/acc1f572ea014b36a3390cc5112c38fbTest

المؤلفون: Hedayatollah Shirzad, Shabnam Bakhshalizadeh, Fariba Esmaeili, Marzieh Ebrahimie, Esmaeil Ebrahimie

المساهمون: Shirzad, Hedayatollah, Esmaeili, Fariba, Bakhshalizadeh, Shabnam, Ebrahimie, Marzieh, Ebrahimie, Esmaeil

المصدر: Molecular and cellular probes. 32

مصطلحات موضوعية: 0301 basic medicine, Embryonal Carcinoma Stem Cells, Cellular differentiation, Green Fluorescent Proteins, synaptophysin, Cell Culture Techniques, Fluorescent Antibody Technique, Germ layer, Biology, antiparkinson drugs, GFP, Transfection, Fluorescence, Embryonal carcinoma, 03 medical and health sciences, Mice, 0302 clinical medicine, stem cells, Selegiline, medicine, Animals, Molecular Biology, neuronal differentiation, selegiline, Neurons, fungi, Cell Differentiation, Cell Biology, medicine.disease, Molecular biology, Transplantation, Antiparkinson drug, Gene Expression Regulation, Neoplastic, 030104 developmental biology, P19 cell, embryonic structures, Stem cell, Chickens, 030217 neurology & neurosurgery

الوصف: Murine P19 embryonal carcinoma (EC) cells are convenient to differentiate into all germ layer derivatives. One of the advantages of P19 cells is that the exogenous DNA can be easily inserted into them. Here, at the first part of this study, we generated stable GFP-expressing P19 cells (P19-GFP+). FACS and western-blot analysis confirmed stable expression of GFP in the cells. We previously demonstrated the efficient induction of neuronal differentiation from mouse ES and EC cells by application of a neuroprotective drug, selegiline In the second part of this study selegiline was used to induce differentiation of P19-GFP+ into stable GFP-expressing neuron-like cells. Cresyl violet staining confirmed neuronal morphology of the differentiated cells. Furthermore, real-time PCR and immunoflourescence approved the expression of neuron specific markers. P19-GFP+ cells were able to survive, migrate and integrated into host tissues when transplanted to developing chick embryo CNS. The obtained live GFP-expressing cells can be used as an abundant source of developmentally pluripotent material for transplantation studies, investigating the cellular and molecular aspects of early differentiation. Refereed/Peer-reviewed

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4afaa593f39a075251c8a553512c7e3eTest
https://pubmed.ncbi.nlm.nih.gov/28013042Test

المؤلفون: Begić, Gabriela

المساهمون: Tomić, Siniša

مصطلحات موضوعية: Nuspojava, Parkinsonova bolest, Dopamin, Antiparkinsonici, Adverse drug reaction, Parkinson's disease, Dopamine, Antiparkinson Drugs, BIOTEHNIČKE ZNANOSTI. Biotehnologija, BIOTECHNICAL SCIENCES. Biotechnology

الوصف: Nuspojava je svaka štetna i neželjena reakcija na lijek. To uključuje nuspojave koje nastaju uz primjenu lijeka unutar odobrenih uvjeta kao i nuspojave koje nastaju uz primjenu lijeka izvan odobrenih uvjeta (predoziranje, primjenu izvan odobrene indikacije ("off-label"), pogrešnu primjenu, zlouporabu i medikacijske pogreške) te nuspojave koje nastaju zbog profesionalne izloženosti. Značaj opterećenja nuspojava za javno zdravstvo najbolje ilustriraju podaci Europske Komisije, koja ocjenjuje da su u EU nuspojave razlogom oko 5% svih hospitalizacija. Nadalje, oko 5% hospitaliziranih bolesnika doživi nuspojavu za vrijeme hospitalizacije, a nuspojave su peti po redu uzrok mortaliteta meĎu hospitaliziranim bolesnicima. Ukupno se procjenjuje da je oko 197.000 smrti godišnje u EU uzrokovano nuspojavama. TakoĎer se ocjenjuje da u EU ukupni direktni troškovi zbog nuspojava iznose godišnje oko 79 milijardi eura. S obzirom da se i prema najkonzervativnijim procjenama smatra da se barem 30% nuspojava može prevenirati, to znači da godišnji troškovi nuspojava koje se mogu spriječiti u EU iznose više od 23,5 milijarde eura. Stoga Europska Komisija ocjenjuje da čak i mala unaprjeĎenja na području sigurnosti primjene lijekova mogu imati velik i značajan utjecaj na javno zdravlje i društvo u cjelini. U Parkinsonovoj bolesti, koncentracija dopamina u bazalnim ganglijima je značajno snižena te farmakološko obnavljanje dopaminergičke aktivnosti levodopom ili dopaminskim agonistima ublažava motoričke simptome. Alternativan i komplementaran pristup je obnova ravnoteže kolinergičkih i dopaminergičkih utjecaja na bazalne ganglije. Najčešće nuspojave uzrokovane levodopom jesu: mučnina, povraćanje, abdominalni grčevi, noćne more, ortostatska hipotenzija, pospanost, diskinezija i, osobito u starijih i dementnih bolesnika, povremene halucinacije. Nuspojave izravnih agonista dopaminskih receptora jesu: sedacija, mučnina, ortostatska hipotenzija, psihoza. Antikolinergički 2 lijekovi imaju mnogo zabilježenih nuspojava kao što su suhoća usta, ...

وصف الملف: application/pdf

العلاقة: https://www.unirepository.svkri.uniri.hr/islandora/object/biotechri:236Test; https://urn.nsk.hr/urn:nbn:hr:193:708397Test; https://www.unirepository.svkri.uniri.hr/islandora/object/biotechri:236/datastream/PDFTest

الإتاحة: https://www.unirepository.svkri.uniri.hr/islandora/object/biotechri:236Test
https://urn.nsk.hr/urn:nbn:hr:193:708397Test
https://www.unirepository.svkri.uniri.hr/islandora/object/biotechri:236/datastream/PDFTest

المؤلفون: Begić, Gabriela

المساهمون: Tomić, Siniša

مصطلحات موضوعية: Nuspojava, Parkinsonova bolest, Dopamin, Antiparkinsonici, Adverse drug reaction, Parkinson's disease, Dopamine, Antiparkinson Drugs, BIOTEHNIČKE ZNANOSTI. Biotehnologija, BIOTECHNICAL SCIENCES. Biotechnology, phil, relig

الوصف: Nuspojava je svaka štetna i neželjena reakcija na lijek. To uključuje nuspojave koje nastaju uz primjenu lijeka unutar odobrenih uvjeta kao i nuspojave koje nastaju uz primjenu lijeka izvan odobrenih uvjeta (predoziranje, primjenu izvan odobrene indikacije ("off-label"), pogrešnu primjenu, zlouporabu i medikacijske pogreške) te nuspojave koje nastaju zbog profesionalne izloženosti. Značaj opterećenja nuspojava za javno zdravstvo najbolje ilustriraju podaci Europske Komisije, koja ocjenjuje da su u EU nuspojave razlogom oko 5% svih hospitalizacija. Nadalje, oko 5% hospitaliziranih bolesnika doživi nuspojavu za vrijeme hospitalizacije, a nuspojave su peti po redu uzrok mortaliteta meĎu hospitaliziranim bolesnicima. Ukupno se procjenjuje da je oko 197.000 smrti godišnje u EU uzrokovano nuspojavama. TakoĎer se ocjenjuje da u EU ukupni direktni troškovi zbog nuspojava iznose godišnje oko 79 milijardi eura. S obzirom da se i prema najkonzervativnijim procjenama smatra da se barem 30% nuspojava može prevenirati, to znači da godišnji troškovi nuspojava koje se mogu spriječiti u EU iznose više od 23,5 milijarde eura. Stoga Europska Komisija ocjenjuje da čak i mala unaprjeĎenja na području sigurnosti primjene lijekova mogu imati velik i značajan utjecaj na javno zdravlje i društvo u cjelini. U Parkinsonovoj bolesti, koncentracija dopamina u bazalnim ganglijima je značajno snižena te farmakološko obnavljanje dopaminergičke aktivnosti levodopom ili dopaminskim agonistima ublažava motoričke simptome. Alternativan i komplementaran pristup je obnova ravnoteže kolinergičkih i dopaminergičkih utjecaja na bazalne ganglije. Najčešće nuspojave uzrokovane levodopom jesu: mučnina, povraćanje, abdominalni grčevi, noćne more, ortostatska hipotenzija, pospanost, diskinezija i, osobito u starijih i dementnih bolesnika, povremene halucinacije. Nuspojave izravnih agonista dopaminskih receptora jesu: sedacija, mučnina, ortostatska hipotenzija, psihoza. Antikolinergički 2 lijekovi imaju mnogo zabilježenih nuspojava kao što su suhoća usta, . ...

العلاقة: https://zir.nsk.hr/islandora/object/biotechri:236Test

الإتاحة: https://zir.nsk.hr/islandora/object/biotechri:236Test